FDA grants Orphan Drug Designation to Affinia’s AFTX-201 for BAG3-associated DCM as the Phase 1/2 UPBEAT trial evaluates the investigational gene therapy.
Written By: Amit Kumar Bharati, BPharm
Reviewed By: Pharmacally Editorial Team
Affinia Therapeutics has received FDA Orphan Drug Designation for AFTX-201, an investigational AAV gene therapy designed to address the underlying genetic cause of BAG3-associated dilated cardiomyopathy (DCM), a rare inherited heart disease characterized by early-onset progressive heart failure, impaired quality of life, and reduced survival. There are currently no approved therapies that target the underlying genetic mechanism of the disease.
The designation marks another regulatory milestone for AFTX-201 following the U.S. Food and Drug Administration’s acceptance of its Investigational New Drug (IND) application and the granting of Fast Track designation earlier this year, which enabled the initiation of the Phase 1/2 UPBEAT clinical trial (NCT07426419). The therapy has also received Orphan Drug Designation from the European Medicines Agency (EMA), further supporting its development for patients with BAG3-associated DCM.
Commenting on the announcement, Hideo Makimura, MD, PhD, Chief Medical Officer of Affinia Therapeutics, said the FDA’s Orphan Drug designation, together with the previously granted Fast Track designation, represents an important milestone for the AFTX-201 program and supports the company’s continued efforts to advance the therapy for people living with BAG3-associated DCM.
AFTX-201 aims to address the underlying genetic cause of BAG3-associated DCM
AFTX-201 is an investigational AAV gene therapy designed to treat BAG3-associated DCM by delivering a functional BAG3 gene directly to cardiac muscle cells through a single intravenous infusion. The therapy utilizes Affinia’s proprietary engineered ATC-187 AAV capsid, which is designed to achieve efficient cardiac transduction at doses approximately five to ten times lower than those typically required with conventional AAV capsids such as AAV9 and AAVrh74.
According to Affinia, preclinical studies demonstrated that AFTX-201 increased BAG3 protein expression in the heart, fully restored cardiac function, reversed structural abnormalities characteristic of BAG3-associated DCM, and improved survival in animal models. These findings support the continued clinical evaluation of the therapy as a potential treatment targeting the underlying genetic defect responsible for the disease.
UPBEAT Phase 1/2 trial actively recruiting patients
AFTX-201 is currently being evaluated in the UPBEAT Phase 1/2 clinical trial open-label, dose-exploration and dose-expansion study enrolling adults with genetically confirmed BAG3-associated dilated cardiomyopathy across multiple clinical sites in the United States and Canada.
Eligible participants are adults aged 18 to 55 years with a BAG3 truncating mutation, left ventricular ejection fraction (LVEF) below 45%, and New York Heart Association (NYHA) Class II or III heart failure despite receiving standard-of-care therapy. The study evaluates patients who experience limitations in performing everyday physical activities because of heart failure.
Participants receive a single intravenous infusion of AFTX-201. The primary objective is to evaluate safety and tolerability over 52 weeks, while secondary and exploratory endpoints include BAG3 protein expression, cardiac function, biomarkers, and preliminary measures of clinical efficacy. Participants will continue long-term follow-up for up to 60 months to evaluate the durability of response and long-term safety.
Regulatory progress strengthens AFTX-201 development
The FDA’s Orphan Drug Designation provides incentives intended to support the development of therapies for rare diseases, including tax credits for qualified clinical trial costs, exemption from certain FDA marketing application fees, and the potential for seven years of market exclusivity following approval.
Combined with the previously granted Fast Track designation, accepted IND application, and EMA Orphan Drug Designation, the latest FDA designation further strengthens the regulatory pathway for AFTX-201 as Affinia advances clinical development.
Published estimates suggest that BAG3 mutations account for approximately 2.3% to 3.6% of dilated cardiomyopathy cases worldwide, highlighting the significant unmet medical need for therapies that address the underlying genetic cause of the disease. As enrollment in the UPBEAT trial continues, future clinical data will determine whether AFTX-201 can provide a new treatment option for patients living with BAG3-associated dilated cardiomyopathy.
References
About the Writer
Amit Kumar Bharti (LinkedIn) is a pharmacy graduate from DPSRU, Delhi and healthcare writer with a strong interest in pharmaceutical research, medical writing, and evidence-based healthcare communication. He is passionate about translating complex scientific and medical information into clear, accurate, and engaging content for healthcare professionals and the pharmaceutical industry. His focus includes emerging therapies, clinical research, and recent advances in medicine.